argenx Q2 FY26 profit rises 93% to $472 million; net sales increase 60% year-over-year to $1.52 billion
ARGX•Label expansion and pipeline updates
The company expanded the U.S. label for VYVGART and VYVGART Hytrulo to all adult gMG serotypes, including triple seronegative patients.
It also kept key readouts on track, with ALKIVIA myositis results due in 3Q26 and EMPASSION MMN data for empasiprubart expected in 4Q26.
Q2 profit and sales growth accelerate
argenx posted 2Q 2026 profit of $472 million, swinging from $245 million a year earlier; operating profit rose 146% year over year to $494 million.
Product net sales climbed 60% year over year to $1.52 billion, rising 17% from 1Q; 1H net sales rose to $2.81 billion.
Costs rise with commercialization and pipeline investment
R&D expenses increased to ; SG&A costs rose to , reflecting franchise commercialization and pipeline investment.
